Cencora (NYSE:COR) Price Target Cut to $355.00 by Analysts at Citigroup

Cencora (NYSE:COR) had its price objective trimmed by Citigroup from $405.00 to $355.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

COR has been the topic of a number of other research reports. Evercore set a $360.00 target price on Cencora in a report on Wednesday, April 8th. Wells Fargo & Company raised their target price on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Barclays raised their target price on Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a report on Friday, February 13th. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, UBS Group lifted their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $391.58.

Cencora Stock Performance

Shares of Cencora stock opened at $254.90 on Thursday. The company has a current ratio of 0.95, a quick ratio of 0.51 and a debt-to-equity ratio of 3.40. The company has a market cap of $49.58 billion, a PE ratio of 19.55, a price-to-earnings-growth ratio of 1.18 and a beta of 0.64. The company has a 50 day moving average of $327.81 and a 200-day moving average of $342.26. Cencora has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period last year, the business earned $4.42 earnings per share. The business’s revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts forecast that Cencora will post 17.58 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s payout ratio is currently 28.85%.

Institutional Trading of Cencora

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Cencora by 13.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after purchasing an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd bought a new stake in shares of Cencora during the third quarter worth about $26,191,000. Mediolanum International Funds Ltd lifted its stake in shares of Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after acquiring an additional 32,138 shares during the period. Chilton Investment Co. Inc. acquired a new position in shares of Cencora in the third quarter worth approximately $459,000. Finally, Advisors Asset Management Inc. lifted its stake in shares of Cencora by 40.3% in the third quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock worth $5,407,000 after acquiring an additional 4,973 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Management raised FY‑2026 adjusted EPS guidance to $17.65–$17.90 and approved a $1 billion share repurchase program — this provides capital‑return support and signals confidence in profitability. Cencora signals FY2026 EPS of 17.65-17.90 while resuming $1B share repurchases
• Positive Sentiment: Cencora announced a quarterly dividend (record May 15; $0.60 per share) and reiterated margin improvement initiatives (OneOncology integration cited as a driver). These cash returns and margin tailwinds can bolster near‑term investor confidence.
• Neutral Sentiment: Major analysts trimmed price targets but kept constructive ratings — Citigroup cut its target to $355 (still a Buy) and Robert W. Baird trimmed to $339 (Outperform). Lower targets reduce near‑term upside expectations even as analyst support remains. Citigroup price target cut Baird price target cut
• Neutral Sentiment: Earnings call transcript and slide deck are available for review — useful for investors wanting management commentary on client dynamics, GLP‑1 margin impacts and remediation steps. Q2 2026 Earnings Call Transcript
• Negative Sentiment: Q2 results missed revenue and adjusted EPS estimates — reported adjusted EPS $4.75 vs. ~$4.82 consensus and revenue ~$78.4B vs. ~$81.1B expected; management flagged U.S. Healthcare Solutions weakness (branded price cuts, lower orders from a large mail‑order client and prior customer losses). That miss triggered the earlier sharp selloff. COR Misses Q2 Earnings and Revenue Estimates
• Negative Sentiment: The stock plunged after the report (hit multi‑month/52‑week lows in intraday trading) as investors focused on near‑term revenue softness and customer mix risks, outweighing the EPS guide raise for some holders. Cencora hits 52-week low after guidance cut
• Negative Sentiment: Notable insider selling and mixed institutional repositioning were flagged in commentary — could amplify short‑term selling pressure if sentiment remains fragile. Quiver Quant summary of reactions & insider activity

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.